



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Harald Wajant

✉ harald.wajant@mail.uni-wuerzburg.de

†These authors have contributed equally to this work

‡These authors have contributed equally to this work

RECEIVED 08 December 2023

ACCEPTED 12 December 2023

PUBLISHED 18 December 2023

CITATION

Gamboa Vargas J, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Peña Mosca J, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2023) Corrigendum: A TNFR2-specific TNF fusion protein with improved *in vivo* activity. *Front. Immunol.* 14:1352525. doi: 10.3389/fimmu.2023.1352525

COPYRIGHT

© 2023 Gamboa Vargas, Wagner, Shaikh, Lang, Medler, Anany, Steinfatt, Peña Mosca, Haack, Dahlhoff, Büttner-Herold, Graf, Viera, Einsele, Wajant and Beilhack. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: A TNFR2-specific TNF fusion protein with improved *in vivo* activity

Juan Gamboa Vargas^{1,2†}, Jennifer Wagner^{3†},
Haroon Shaikh^{1,2}, Isabell Lang³, Juliane Medler³,
Mohamed Anany^{3,4}, Tim Steinfatt¹, Josefina Peña Mosca^{1,2},
Stephanie Haack¹, Julia Dahlhoff¹, Maike Büttner-Herold⁵,
Carolin Graf¹, Estibaliz Arellano Viera¹, Hermann Einsele¹,
Harald Wajant^{3*‡} and Andreas Beilhack^{1,2‡}

¹Interdisciplinary Center for Clinical Research Laboratory, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany, ²Graduate School of Life Sciences, Würzburg University, Würzburg, Germany, ³Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany, ⁴Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt, ⁵Department of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

KEYWORDS

agonist, GvHD, regulatory T cells, serum retention, TNF, TNFR2

A Corrigendum on

A TNFR2-specific TNF fusion protein with improved *in vivo* activity

by Vargas JG, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Mosca JP, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2022) *Front. Immunol.* 13:888274. doi: 10.3389/fimmu.2022.888274

Incorrect Affiliation

In the published article, there was an error in affiliation “4”. Instead of “Department of Microbial Biotechnology, Institute of Biotechnology, Giza, Egypt”, it should be “Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.